Trustmark National Bank Trust Department Makes New $213,000 Investment in Hologic, Inc. (NASDAQ:HOLX)

Trustmark National Bank Trust Department bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the third quarter, HoldingsChannel.com reports. The firm bought 2,619 shares of the medical equipment provider’s stock, valued at approximately $213,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in HOLX. Innealta Capital LLC acquired a new position in shares of Hologic during the 2nd quarter worth approximately $25,000. Wolff Wiese Magana LLC acquired a new position in shares of Hologic during the 3rd quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic during the 1st quarter worth approximately $37,000. Sunbelt Securities Inc. acquired a new position in shares of Hologic during the 2nd quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the subject of several analyst reports. Raymond James raised their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Mizuho dropped their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Leerink Partners reduced their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Price Performance

HOLX stock opened at $78.68 on Friday. The stock has a market cap of $18.28 billion, a price-to-earnings ratio of 23.63, a PEG ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The business has a 50 day moving average price of $80.49 and a 200 day moving average price of $78.30. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.89 earnings per share. Equities research analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.